Form 4 for MIST Milestone Pharmaceuticals Inc.
Accepted 2026-01-28 00:00:00 ET · period of report 2025-12-12 · accession 0001910985-26-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-01-28 | 2025-12-15+ | MIST | Bharucha David | Chief Medical Off | S - Sale+OE | $2.25 | -70.3K | 105.3K | -40% | -$158.2K |
| D | 2026-01-28 | 2026-01-26 | MIST | Bharucha David | Chief Medical Off | M - OptEx | — | +20.1K | 125.4K | +19% | — |
| D | 2026-01-28 | 2025-12-12 | MIST | Bharucha David | Chief Medical Off | A - Grant | — | +100.0K | 163.3K | +158% | — |
| D | 2026-01-28 | 2026-01-26 | MIST | Bharucha David | Chief Medical Off | M - OptEx | $0.00 | -20.1K | 60.3K | -25% | $0 |
| D | 2026-01-28 | 2025-12-12 | MIST | Bharucha David | Chief Medical Off | A - Grant | $0.00 | +100.0K | 100.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2026-01-26 | S | D | 12,245 | $1.93 | 113,181 | D | — | — | (F4) The price reported is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 2 | Common | Common Shares | 2026-01-26 | M | A | 20,100 | — | 125,426 | D | — | — | (F5) Each RSU represents a contingent right to receive one common share. |
| 3 | Common | Common Shares | 2025-12-12 | A | A | 100,000 | — | 163,333 | D | — | — | (F1) Represents a performance stock unit ("PSU") award that vested upon the certification by the Compensation Committee of the Board of Directors of the Issuer that the U.S. Food and Drug Administration has provided a New Drug Application Approval Letter granting approval of Cardamyst (etripamil). (F2) Each PSU represents a contingent right to receive one common share. |
| 4 | Common | Common Shares | 2025-12-15 | S | D | 58,007 | $2.32 | 105,326 | D | — | — | (F4) The price reported is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 5 | Derivative | Restricted Stock Units | 2026-01-26 | M | D | 20,100 | $0.00 | 60,300 | D | — · — to — | 20,100 Common Shares | (F5) Each RSU represents a contingent right to receive one common share. (F7) One-fourth (1/4th) of the shares subject to the RSU award vested or will vest on each of January 26, 2026, January 26, 2027, January 26, 2028 and January 26, 2029, subject to the Reporting Person continuing to provide service through each such date. |
| 6 | Derivative | Employee Stock Option (right to buy) | 2025-12-12 | A | A | 100,000 | $0.00 | 100,000 | D | $1.74 · — to 2034-05-06 | 100,000 Common Shares | (F6) 50% of the option will vest on June 12, 2026 and 50% will vest on December 12, 2026, subject to the Reporting Person continuing to provide service through each such date. |